KOSDAQIT & Software263700

Carelabs

₩1,990▼ 3.40%2026-11-18 close
Market Cap
₩38.6B
Turnover
₩60,254,539
Volume
30K
Shares out.
19.4M
PER
—
PBR
0.6×
EPS
-₩371
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating losses persist; 2025 net profit swing rests on non-operating gains

Carelabs recorded operating losses every year from 2022 through 2025, and its 2025 swing to attributable net profit was linked in its disclosure to higher non-operating income from an asset disposal.

  1. 1

    Revenue fell from KRW 87.6 billion in 2022 to KRW 81.7 billion in 2025, the smallest year of the 2022–2025 period.

  2. 2

    Operating loss narrowed from KRW 11.6 billion in 2023 to KRW 2.88 billion in 2025, yet the company has posted operating losses in four consecutive years from 2022 to 2025.

  3. 3

    Attributable net profit of KRW 19.2 billion in 2025 contrasted with an operating loss of KRW 2.88 billion, a gap that appears to come from non-operating items.

  4. 4

    Q1 2026 operating profit of KRW 675 million was followed by operating losses of KRW 723 million in Q2 and KRW 3.56 billion in Q3, a wider loss.

  5. 5

    The debt-to-equity ratio fell to 43.9% at end-2025 from 160.6% in 2024, and the price-to-book ratio sits below 1x.

02

Business structure

Carelabs is a digital healthcare company centered on mobile healthcare and beauty-care platforms. Founded in 2012 and listed on KOSDAQ in 2018, it owns subsidiaries including the telehealth reservation platform Goodoc and the cosmetic-procedure information platform Babitalk.

Goodoc connects users with hospital reservations and remote care, while Babitalk is an app for sharing cosmetic procedure information. The company's business units are platforms, digital advertising marketing, and CRM software solutions for medical institutions, which it says work together to create synergies.

As of Q1 2019, the revenue mix was 32% platforms, 37% healthcare digital marketing, 14% healthcare solutions and 16% social network. The largest shareholder changed to a new holding company as of the January 2023 report, and the company subsequently pursued management efficiency measures.

At its March 27, 2026 shareholder meeting, the company said it would make senior care the first year of full-scale new business, and it added business purposes such as health functional foods, cosmetics and quasi-drugs manufacturing and distribution to its articles of incorporation. It has also said it plans to link data accumulated by Goodoc and Babitalk with AI.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩21.2B-₩600M−2.8%
2025Q4₩14.9B-₩5.7B−38.2%
2026Q1₩20.5B₩700M3.3%
2026Q2₩17.4B-₩700M−4.2%
2026Q3₩18.6B-₩3.6B−19.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩87.6B-₩6.4B-₩26.1B−7.3%−30.9%97.3%
2023₩81.8B-₩11.6B-₩24.5B−14.2%−35.7%116.1%
2024₩83.2B-₩4.5B-₩20.3B−5.4%−41.9%160.6%
2025₩81.7B-₩2.9B₩19.2B−3.5%28.0%43.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue fell from KRW 87.6 billion in 2022 to KRW 81.8 billion in 2023 (down 6.6% year on year), rebounded to KRW 83.2 billion in 2024 (up 1.7%), and declined to KRW 81.7 billion in 2025 (down 1.8%). Among 2022–2025, 2022 was the largest year by revenue and 2025 the smallest.

Operating loss widened from KRW 6.38 billion in 2022 to KRW 11.6 billion in 2023, then narrowed to KRW 4.46 billion in 2024 and KRW 2.88 billion in 2025. The operating margin moved from -7.3% in 2022 to -14.2% in 2023, then improved to -5.4% in 2024 and -3.5% in 2025.

Attributable net loss shrank from KRW 26.1 billion in 2022 to KRW 24.5 billion in 2023 and KRW 20.3 billion in 2024, and the company swung to attributable net profit of KRW 19.2 billion in 2025. Net profit including non-controlling interests, at KRW 19.5 billion, is a separate figure from attributable net profit.

The company's March 2026 disclosure attributed the 2025 swing to management efficiency, which reduced losses, and to higher non-operating income from an asset disposal.

The gap between an operating loss of KRW 2.88 billion and attributable net profit of KRW 19.2 billion suggests non-operating items, not core earnings recovery, drove the swing.

Quarterly, revenue of KRW 21.2 billion and an operating loss of KRW 587 million in Q3 2025 were followed by a Q4 2025 operating loss of KRW 5.71 billion on revenue of KRW 14.9 billion (down 29.3% from the prior quarter).

Q1 2026 revenue of KRW 20.5 billion (up 37.4% quarter on quarter) produced operating profit of KRW 675 million, but Q2 turned to an operating loss of KRW 723 million on revenue of KRW 17.4 billion.

Q3 2026 revenue of KRW 18.6 billion (down 11.9% year on year) came with a wider operating loss of KRW 3.56 billion, and attributable net losses over the latest four quarters total KRW 7.61 billion. One research site put first-half 2026 revenue down 16.9% year on year.

It attributed weakness to lower demand for high-priced procedures at Babitalk amid an economic slowdown, and to labor supply imbalances in elder and nursing care.

05

Industry analysis

Carelabs' core businesses are Goodoc, a telehealth reservation platform, and Babitalk, a cosmetic-procedure information platform. Demand for remote medical reservation services rises and falls with the broader demand for non-face-to-face care.

Growth in non-face-to-face medical demand was cited as a driver of strong results in the past, but revenue has since declined from KRW 87.6 billion in 2022 to KRW 81.7 billion in 2025.

On the beauty side, an economic slowdown has reduced demand for high-priced procedures, which has been identified as a pressure point for Babitalk. In elder and nursing care, poor working conditions and institutional limits have deepened labor supply imbalances.

Senior care was shaped in a September 2023 interview, when the CEO said the company was preparing a care-town business aimed at active seniors who are not eligible for long-term care benefits. The same interview set a target of opening a first site in 2025, with the site still under review.

After being acquired by a Wonik group entity, the company pursued management efficiency and sold some business units. In terms of cycle, the business appears to be in a phase of seeking profitability recovery after the boost from non-face-to-face demand faded.

Competition in healthcare platforms centers on winning users against other platforms, and the company is positioning its data and AI services as a differentiator.

06

Outlook

The company's medium-term direction centers on combining senior care and other new businesses with data from its existing platforms.

At its March 2026 shareholder meeting it declared senior care the first year of full-scale new business, and it added manufacturing and distribution purposes to its articles of incorporation.

Whether the first-site target set in a September 2023 interview, for 2025, has actually been pursued should be checked against upcoming annual and shareholder meeting materials.

In the near term, Q4 2026 results will shape the direction of full-year operating results, since the Q3 2026 operating loss widened to KRW 3.56 billion. The first checkpoint is how 2026 annual revenue compares with KRW 81.7 billion in 2025 in the FY2026 annual report.

It is also necessary to check whether operating results extend the losses recorded from 2022 through 2025. The timing of revenue contributions from AI-linked data services and senior care has not yet been presented in company disclosures.

With the debt-to-equity ratio down to 43.9% in 2025, the financial burden of new-business investment is smaller than in 2024. However, because the 2025 profit swing relied on non-operating items, whether the earnings structure shifts toward core operations is the key point to confirm.

07

Valuation

PER
—
PBR
0.6×
ROE
-11.1%
EPS
-₩371
BPS
₩3,376
Dividend per share
₩0

Because attributable net losses over the latest four quarters are aggregated, the price-to-earnings ratio is not calculated. With earnings-based multiples difficult to compare, asset-based measures carry more weight in the analysis.

The price-to-book ratio sits below 1x, and market capitalization is below the size of attributable equity. The 2025 swing to positive attributable net profit relied largely on non-operating items, so multiples should be read alongside the quality of the earnings structure.

The dividend yield is at a 0% level, so comparisons based on dividends do not apply. Interpretation of valuation depends on whether operating results turn to a sustained profit and whether the capital structure holds.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Narrowing losses and lighter debt

Operating loss narrowed from KRW 11.6 billion in 2023 to KRW 2.88 billion in 2025, and the operating margin improved from -14.2% to -3.5%. The debt-to-equity ratio fell to 43.9% in 2025 from 160.6% in 2024. Q1 2026 posted operating profit of KRW 675 million, which supporters cite as evidence of improvement.

2025 profit swing and capital base

Attributable net profit reached KRW 19.2 billion in 2025, after an attributable net loss of KRW 20.3 billion in 2024. Total equity at end-2025 was KRW 74.6 billion and total liabilities KRW 32.8 billion. The retained capital base can be read as a factor in assessing capacity for new-business spending.

Senior care and data-linked plans

At its March 27, 2026 shareholder meeting, the company said senior care would be the first year of full-scale new business. The amendment to the articles of incorporation provides a basis for manufacturing and distributing products in new areas such as health functional foods. Plans to link data from Goodoc and Babitalk with AI are read as an expansion built on existing platform assets.

09

Bear factors

Four straight operating losses and wider recent losses

Operating losses have been recorded in four consecutive years from 2022 through 2025, and they continued in Q2 and Q3 2026. The Q3 2026 operating loss of KRW 3.56 billion was wider than the prior quarter. Attributable net losses over the latest four quarters total KRW 7.61 billion.

Continued revenue decline

Revenue declined from KRW 87.6 billion in 2022 to KRW 81.7 billion in 2025. Q3 2026 revenue of KRW 18.6 billion was down 11.9% year on year. One research site put first-half 2026 revenue down 16.9%, and attributed part of the weakness to lower demand for high-priced procedures at Babitalk.

Quality of the profit swing

Attributable net profit was positive in 2025, while the operating loss for the same year was KRW 2.88 billion. The company's disclosure cited higher non-operating income from an asset disposal as a factor in the swing. Whether core profit recovery continues must be confirmed from 2026 full-year operating results.

10

Risk factors

Core profitability

The operating margin has improved but remains negative, and operating losses continued in Q2 and Q3 2026. If costs are not reduced while revenue declines, losses could persist. The FY2026 annual report's operating results will show the extent of this.

New business execution

Senior care was presented in a September 2023 interview with a target of opening a first site in 2025. Labor supply imbalances in elder and nursing care could constrain execution. The investment scale and revenue model of the new business are items to confirm in periodic reports.

Earnings quality and ownership

The 2025 profit swing relied heavily on non-operating items, so a similar effect may not recur. The largest shareholder changed as of the January 2023 report, and ownership shifts could affect management direction. It is necessary to check how much of the profit came from one-time asset disposal gains.

11

What to watch next

  1. By end of March 2027

    Annual revenue and operating results in the FY2026 annual report. Revenue direction against KRW 81.7 billion in 2025 and the Q4 operating loss will determine the full-year loss.

  2. Around the regular shareholder meeting in March 2027

    Whether senior care business plans are concretized and how the new business purposes added to the articles are being executed. Progress against the first-site target set for 2025 should also be checked.

  3. By May 15, 2027

    Operating results in the Q1 2027 quarterly report. This shows whether the operating losses running since Q2 2026 continue or whether another profitable quarter emerges.

  4. After January 2027 (schedule not confirmed)

    Whether preliminary Q4 2026 results are released and their content. Preliminary figures should be read separately from figures confirmed in periodic reports.

12

Overall view

Carelabs recorded operating losses from 2022 through 2025, but the size of its operating loss and its operating margin have improved since 2023. The 2025 swing to attributable net profit of KRW 19.2 billion was driven by higher non-operating income and should be read separately from any core profit recovery.

In 2026, a Q1 operating profit was followed by operating losses in Q2 and Q3, with the Q3 loss widening to KRW 3.56 billion. Revenue in 2025 was KRW 81.7 billion, below 2022, and Q3 2026 revenue fell 11.9% year on year.

Financially, the debt-to-equity ratio was 43.9% and total equity KRW 74.6 billion at end-2025, a lighter burden than in 2024. The senior care business and the added business purposes signal direction, but the timing of revenue contributions has not yet been presented.

The next checkpoints are full-year operating results and the Q4 loss in the FY2026 annual report, and whether the new businesses contribute revenue.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. ssl.pstatic.net
  2. thevc.kr
  3. comp.fnguide.com
  4. m.news.nate.com
  5. comp.wisereport.co.kr
  6. file.alphasquare.co.kr
  7. pharm.edaily.co.kr
  8. m.thinkpool.com
  9. sedaily.com
  10. edaily.co.kr
  11. comp.fnguide.com
  12. goinsider.kr
  13. tradingkey.com
  14. judal.co.kr
  15. dealsite.co.kr
  16. judal.co.kr
  17. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis